News

CellSight researchers at the Sue Anschutz-Rodgers Eye Center were published for a discovery that could lead to early diagnosis and intervention of dry age-related macular degeneration.

Proposal hints at the use of generative adversarial network (GAN) for applications in macular surgery

Mark Wieland, MD, explores how Port Delivery System with ranibizumab provides drug delivery over an extended period.

PRS can modify disease outcomes due to other genes, such as MYOC.

Veeral Sheth, MD, presents research finding faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.

Ines Lains, MD, PhD, explores how mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

Nathan Hall, BS, MS, presents research on how epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.

Roger A. Goldberg, MD, MBA, notes how small misalignments in the plunger can lead to possible overdosing.

Felipe Medeiros, MD, presents results from a phase 3 clinical extension study of the bimatoprost implant that found patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fiends.

Shady Awwad, MD, discusses how the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.

Gareth Lema, MD, PhD, spotlights a treatment could provide benefits for patients with central retinal artery occlusion.

The results are in! Check out how your institution ranked in the 2021 Ophthalmology Times® Best Program Survey.

Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Dilsher Dhoot, MD, reports results of the KESTREL and KITE trials, in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

“Real talk” on new devices gives surgeons, patients decision-making insights

Diagnostics, imaging, and therapeutics pave the way for better outcomes.

Investigators from the University of Maryland found that uncovering the mechanism of vision loss in Usher syndrome yields additional drug targets for eventual development of better therapies.

Ophthalmologist outlines his journey with the procedure as a late adopter.

According to a team of investigators in Israel, after a third dose of the Pfizer-BioNTech COVID-19 vaccine, the antibody titers increased significantly in individuals over the age of 60.

Unity Biotechnology announces improvement in visual acuity sustained through 24 weeks following single dose of UBX1325 in Phase 1 study of patients with advanced vascular eye disease.

Alcon this week announced its plans to acquire glaucoma surgery device maker Ivantis Inc. in a $475 million deal.

Retinal and choroidal changes were observed in study.

Procedure transfers intact donor nerve fibers to the cornea.

In light of newly published fee schedules that include low payment rates for LipiFlow, Cynthia Matossian, MD, FACS, ABES, advises on how eyecare professionals should advocate for their patients and practices.

Targeted antibody testing and therapy offers new options for ophthalmologists

Perspectives from a pediatric ophthalmologist and mother.

Pilot study tests the technology to obtain remote fundus imaging of patients.